Wugen CAR-T Therapy WU-CART-007 Shows Promise for T-Cell Leukemia and Lymphoma

Mar 30, 2026-

Researchers at Washington University School of Medicine in St. Louis have developed a novel CAR-T cell therapy, WU-CART-007 (soficabtagene geleucel), which has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA). The therapy is being developed by Wugen, a biotechnology company spun out of WashU and located in the Cortex Innovation District in St. Louis. The therapy targets rare and aggressive T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL)—diseases that historically have had limited treatment options and poor outcomes when relapse occurs.

T-cell malignancies arise from malignant transformations of T lymphocytes, key components of the adaptive immune system. These cancers often prove resistant to conventional chemotherapy or relapse after initial treatment. Allogeneic stem cell transplantation remains the only potentially curative therapy, but patients must first achieve remission, which is difficult with current treatments. As a result, new targeted immunotherapies are urgently needed for these patients.

WU-CART-007 represents a significant innovation in cell-based immunotherapy, particularly because of the challenges associated with targeting T-cell cancers. Unlike CAR-T therapies for B-cell malignancies, which have achieved regulatory approvals over the past decade, CAR-T approaches for T-cell cancers face the problem of fratricide—where engineered T cells attack each other because they share the same target antigens as the malignant cells. Researchers led by Dr. John F. DiPersio, director of the Center for Gene and Cellular Immunotherapy at WashU Medicine and Siteman Cancer Center, engineered the therapy to overcome this issue using advanced genetic modifications that prevent the therapeutic cells from destroying themselves.

Early clinical results from a Phase 1 multi-center trial conducted across the United States, Australia, and Europe have shown encouraging outcomes. The study enrolled 28 adult and adolescent patients with relapsed or refractory T-cell lymphoblastic cancers. Among evaluable patients, 91% demonstrated a meaningful clinical response, with approximately three-quarters achieving complete remission. Several patients subsequently proceeded to stem cell transplantation, and follow-up data between six and twelve months showed continued disease control.

Detailed findings from the trial were published in the peer-reviewed journal Blood, highlighting both the therapy’s strong antitumor activity and a manageable safety profile. These results helped support the FDA’s decision to grant Breakthrough Therapy designation, which is intended to accelerate the development and regulatory review of promising treatments for serious or life-threatening conditions.

Another key feature of WU-CART-007 is its allogeneic “off-the-shelf” design. Unlike autologous CAR-T therapies that must be manufactured individually from each patient’s cells, WU-CART-007 is produced using donor-derived cells that can be prepared in advance. This approach may significantly reduce manufacturing time and enable faster treatment, which is particularly important for patients with rapidly progressing cancers.

Development of the therapy reflects a strong collaboration between academic research, clinical innovation, and biotechnology entrepreneurship. Wugen was co-founded by WashU investigators including Dr. Matthew Cooper, who now serves as the company’s Chief Scientific Officer, alongside Dr. DiPersio and other researchers.

A Phase 2 clinical trial is currently underway to further evaluate the therapy’s efficacy and safety. Adult patients are being treated under the leadership of Dr. Armin Ghobadi at Siteman Cancer Center, while pediatric patients are treated through Siteman Kids, led by Dr. Thomas Pfeiffer.

With continued clinical development, WU-CART-007 could represent a major advance in CAR-T therapy for T-cell malignancies, offering a targeted, rapidly deployable treatment option for patients who currently face extremely limited therapeutic alternatives.